Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann King

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNAAnthony T C Chan, Brigette B Y Ma, Y M Dennis Lo, et al.
The New England Journal of Medicine|August 10, 2017
Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal CancerK C Allen Chan, John K S Woo, Ann King, et al.
Cell Reports|May 31, 2025
BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathwaysRahim Hirani, Subhiksha Nandakumar, Nabila Zaman, et al.
NEJM Evidence|February 6, 2024
Plasma Epstein-Barr Virus DNA and Risk of Future Nasopharyngeal CancerK C Allen Chan, W K Jacky Lam, Ann King, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNAAnthony T C Chan, Brigette B Y Ma, Y M Dennis Lo, et al.
The New England Journal of Medicine|August 10, 2017
Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal CancerK C Allen Chan, John K S Woo, Ann King, et al.
Cell Reports|May 31, 2025
BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathwaysRahim Hirani, Subhiksha Nandakumar, Nabila Zaman, et al.
NEJM Evidence|February 6, 2024
Plasma Epstein-Barr Virus DNA and Risk of Future Nasopharyngeal CancerK C Allen Chan, W K Jacky Lam, Ann King, et al.
Pageof 5